NCT04696042View on ClinicalTrials.gov

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 30, 2024

Study Completion Date

January 27, 2025

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Lanreotide autogel

Lanreotide autogel 90-120 mcg, every 4 weeks

Trial Locations (1)

138-736

Changhoon Yoo, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT04696042 - Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs | Biotech Hunter | Biotech Hunter